Items where Author is "Arnold, D."

Article

Knoedler, M. and Gauler, T. C. and Gruenwald, V. and Matzdorff, A. and Schroeder, M. and Dietz, A. and Jordan, W. -O. and Arnold, D. and Hennemann, B. and Hofele, C. and Weissinger, F. and Eberhardt, W. and Keilholz, U. (2013) Phase II Study of Cetuximab in Combination with Docetaxel in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck after Platinum-Containing Therapy: A Multicenter Study of the Arbeitsgemeinschaft Internistische Onkologie. ONCOLOGY, 84 (5). pp. 284-289. ISSN 0030-2414

Al-Batran, S-E and Hofheinz, R. and Homann, N. and Illerhaus, G. and Martens, U. M. and Stoehlmacher-Williams, J. and Schmalenberg, H. and Luley, K. and Prasnikar, N. and Egger, M. and Probst, S. and Hartmann, J. T. and Moehler, M. H. and Arnold, D. and Fischbach, W. and Pauligk, C. and Moenig, S. and Piso, P. and Jaeger, E. (2011) Defining two prognostic groups of metastatic gastric cancer: FLOT3 trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). ONKOLOGIE, 34 (Suppl6). p. 102. ISSN 0378-584X

Al-Batran, S. and Hofheinz, R. and Homann, N. and Illerhaus, G. and Martens, U. M. and Stoehlmacher-Williams, J. and Schmalenberg, H. and Luley, K. B. and Prasnikar, N. and Egger, M. and Probst, S. and Hartmann, J. T. and Moehler, M. H. and Arnold, D. and Fischbach, W. and Pauligk, C. and Moenig, S. P. and Piso, P. and Jaeger, E. (2011) Defining two prognostic groups of metastatic gastric cancer: FLOT3 trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). JOURNAL OF CLINICAL ONCOLOGY, 29 (15supp): 4070. ISSN 0732-183X, 1527-7755

Liersch, T. and Weiss, C. and Dellas, K. and Hipp, M. and Sauer, R. and Roedel, C. and Arnold, D. (2011) Effect of pathohistologic complete remission (pCR) rate on the prediction of long-term prognosis following chemoradiotherapy (XRT) with cetuximab (Cet), capecitabine (CAP), and oxaliplatin (OX; Cet-CAPOX) in patients (pts) with locally advanced rectal cancer (LARC). JOURNAL OF CLINICAL ONCOLOGY, 29 (15supp): e14035. ISSN 0732-183X, 1527-7755

Weiss, C. and Liersch, T. and Arnold, D. and Dellas, K. and Hinke, A. and Hipp, M. and Balermpas, P. and Roedel, F. and Sauer, R. and Roedel, C. (2011) Preoperative Radiotherapy with Capecitabine, Oxaliplatin and Cetuximab in the Treatment of locally advanced Rectal Carcinoma: Long Term Results of a Phase II Study. STRAHLENTHERAPIE UND ONKOLOGIE, 187 (Snr.1). p. 122. ISSN 0179-7158

Dellas, K. and Roedel, F. and Kappler, M. and Hipp, M. and Bataille, F. and Vordermark, D. and Hartmann, A. and Roedel, C. and Arnold, D. (2010) BIOMARKER PROFILES ARE NOT OF PREDICTIVE VALUE FOR RESPONSE AND OUTCOME IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER UNDERGOING CETUXIMAB-BASED PREOPERATIVE CHEMORADIOTHERAPY. ANNALS OF ONCOLOGY, 21 (Suppl8). viii212. ISSN 0923-7534

Dellas, K. and Roedel, F. and Arnold, D. and Kappler, M. and Hipp, M. and Bataille, F. and Vordermark, D. and Roedel, C. and Hartmann, A. (2010) EGFR, PTEN, and survivin expression in pre- and posttherapeutic specimens does not predict a clinical benefit from preoperative chemoradiation with cetuximab in patients (pts) with locally advanced rectal cancer (LARC). JOURNAL OF CLINICAL ONCOLOGY, 28 (15supp). ISSN 0732-183X, 1527-7755

Dellas, K. and Roedel, F. and Arnold, D. and Kappler, M. and Hipp, M. and Bataille, F. and Vordermark, D. and Hartmann, A. and Roedel, C. (2010) The Expressopn of EGFR, PTEN and Survivin in pre-and post-therapeutic tumor material has no predictive value for clinical outcome after preoperative chemoradiation plus cetuximab in patients with locally advanced rectal cancer (LARC). STRAHLENTHERAPIE UND ONKOLOGIE, 186 (1Suppl). pp. 20-21. ISSN 0179-7158

Knoedler, M. and Gauler, T. C. and Matzdorff, A. and Dietz, A. and Gruenwald, V. and Arnold, D. and Hennemann, B. and Schroeder, M. and Hofele, C. and Schmittel, A. and Keilholz, U. (2008) Phase II trial to evaluate efficacy and toxicity of cetuximab plus docetaxel in platinum pretreated patients with recurrent and/or metastatic head and neck cancer. JOURNAL OF CLINICAL ONCOLOGY, 26 (15supp): 6066. ISSN 0732-183X

Arnold, D. and Hipp, M. and Liersch, T. and Dellas, K. and Koelbl, O. and Hohenberger, W. and Lordick, F. and Suelberg, H. and Sauer, R. and Roedel, C. (2007) Cetuximab, capecitabine, and oxaliplatin (Cet-CapOx) with concurrent radiotherapy (RT) in advanced rectal cancer (RC): Results of a phase I/II trial. JOURNAL OF CLINICAL ONCOLOGY, 25 (18supp): 4042. ISSN 0732-183X, 1527-7755

Roedel, C. and Hipp, M. and Arnold, D. and Reese, T. and Lordick, F. and Sauer, R. (2006) Cetuximab in combination with capecitabine, oxaliplatin and concomitant radiotherapy (CET-CAPOX-RT) as preoperative therapy for rectal cancer. STRAHLENTHERAPIE UND ONKOLOGIE, 182 (Suppl1). p. 20. ISSN 0179-7158

Roedel, C. and Arnold, D. and Hipp, M. and Sauer, R. (2006) Cetuximab in combination with capecitabine, oxaliplatin and concomitant radiotherapy (CET-CAPOX-RT) as preoperative therapy for rectal cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66 (3Supp1). S82-S83. ISSN 0360-3016, 1879-355X

Sauer, R. and Hipp, M. and Liersch, T. and Arnold, D. and Roedel, C. (2006) Multicenter phase II trial of preoperative radiotherapy with concurrent and adjuvant capecitabine and oxaliplatin in locally advanced rectal cancer. ANNALS OF ONCOLOGY, 17 (Suppl1). i14. ISSN 0923-7534

Arnold, D. and Hipp, M. and Reese, T. and Hohenberger, W. and Liersch, T. and Lordick, F. and Suelberg, H. and Sauer, R. and Roedel, C. (2006) Phase I/II study of cetuximab, capecitabine and oxaliplatin (CAPOX) combined with standard radiotherapy (RTX) as neoadjuvant treatment of advanced rectal cancer (RC). JOURNAL OF CLINICAL ONCOLOGY, 24 (18Supp): 3574. 164S. ISSN 0732-183X

Conference or Workshop Item

Knoedler, M. K. and Gauler, T. C. and Matzdorff, A. and Jordan, O. and Schroeder, M. and Gruenwald, V. and Dietz, A. and Hennemann, B. and Arnold, D. and Keilholz, U. (2008) CETUXIMAB PLUS DOCETAXEL AS TREATMENT FOR RECURRENT AND/OR METASTATIC HEAD AND NECK CANCER. In: 33rd European Society for Medical Oncology Congress, September 12-16, 2008, Stockholm, Sweden.